Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 4.09
NXTM's Cash-to-Debt is ranked higher than
61% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. NXTM: 4.09 )
Ranked among companies with meaningful Cash-to-Debt only.
NXTM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.5  Med: 4.09 Max: No Debt
Current: 4.09
Equity-to-Asset 0.65
NXTM's Equity-to-Asset is ranked higher than
59% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. NXTM: 0.65 )
Ranked among companies with meaningful Equity-to-Asset only.
NXTM' s Equity-to-Asset Range Over the Past 10 Years
Min: -4.58  Med: 0.62 Max: 0.89
Current: 0.65
-4.58
0.89
Piotroski F-Score: 5
Altman Z-Score: 7.64
Beneish M-Score: -2.21
WACC vs ROIC
5.54%
-3.04%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -1.33
NXTM's Operating Margin % is ranked lower than
62% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.86 vs. NXTM: -1.33 )
Ranked among companies with meaningful Operating Margin % only.
NXTM' s Operating Margin % Range Over the Past 10 Years
Min: -100.2  Med: -7.25 Max: -1.17
Current: -1.33
-100.2
-1.17
Net Margin % -1.25
NXTM's Net Margin % is ranked lower than
63% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.79 vs. NXTM: -1.25 )
Ranked among companies with meaningful Net Margin % only.
NXTM' s Net Margin % Range Over the Past 10 Years
Min: -97.39  Med: -8.9 Max: -1.3
Current: -1.25
-97.39
-1.3
ROE % -2.34
NXTM's ROE % is ranked lower than
64% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. NXTM: -2.34 )
Ranked among companies with meaningful ROE % only.
NXTM' s ROE % Range Over the Past 10 Years
Min: -54.8  Med: -13.28 Max: -2.43
Current: -2.34
-54.8
-2.43
ROA % -1.48
NXTM's ROA % is ranked lower than
62% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.23 vs. NXTM: -1.48 )
Ranked among companies with meaningful ROA % only.
NXTM' s ROA % Range Over the Past 10 Years
Min: -37.42  Med: -7.59 Max: -1.53
Current: -1.48
-37.42
-1.53
ROC (Joel Greenblatt) % -4.00
NXTM's ROC (Joel Greenblatt) % is ranked lower than
62% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.88 vs. NXTM: -4.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NXTM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -145.34  Med: -30.09 Max: -3.62
Current: -4
-145.34
-3.62
3-Year Revenue Growth Rate 9.10
NXTM's 3-Year Revenue Growth Rate is ranked higher than
68% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. NXTM: 9.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NXTM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 9.5 Max: 332.9
Current: 9.1
0
332.9
3-Year EBITDA Growth Rate 58.60
NXTM's 3-Year EBITDA Growth Rate is ranked higher than
92% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. NXTM: 58.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NXTM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -61.9  Med: -21.05 Max: 58.6
Current: 58.6
-61.9
58.6
3-Year EPS without NRI Growth Rate -39.10
NXTM's 3-Year EPS without NRI Growth Rate is ranked lower than
90% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. NXTM: -39.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NXTM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -39.1  Med: -26.9 Max: 1.1
Current: -39.1
-39.1
1.1
» NXTM's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

NXTM Guru Trades in Q2 2016

Paul Tudor Jones 14,241 sh (New)
Joel Greenblatt 18,781 sh (New)
Steven Cohen Sold Out
RS Investment Management 2,154,390 sh (-32.22%)
Jim Simons 158,483 sh (-66.90%)
» More
Q3 2016

NXTM Guru Trades in Q3 2016

Alan Fournier 397,365 sh (New)
Jim Simons 250,983 sh (+58.37%)
Steven Cohen 200,000 sh (unchged)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
» More
Q4 2016

NXTM Guru Trades in Q4 2016

Paul Tudor Jones 8,876 sh (New)
Alan Fournier 1,927,408 sh (+385.05%)
Jim Simons 84,783 sh (-66.22%)
» More
Q1 2017

NXTM Guru Trades in Q1 2017

Jim Simons 146,983 sh (+73.36%)
Alan Fournier 1,927,408 sh (unchged)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NXTM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 334510    SIC: 3845
Compare:NYSE:GKOS, NYSE:HYH, NAS:MMSI, NAS:NVCR, OTCPK:TOPCF, NAS:ATRI, NAS:LMNX, NAS:OSUR, NYSE:HAE, NAS:IRTC, NAS:ATRC, NAS:ANGO, NAS:LMAT, NAS:MLAB, NAS:PODD, AMEX:CRHM, NAS:PLSE, OTCPK:ANSLF, NAS:ELGX, NAS:ATRS » details
Traded in other countries:N5X.Germany,
Headquarter Location:USA
NxStage Medical Inc is a medical technology company that develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure.

NxStage Medical develops and manufactures products and services for patients with chronic or acute kidney failure. The firm operates in three segments: System One, In-Center, and Services. The System One segment contributes the majority of revenue. It sells and rents the System One portable hemodialysis systems and related consumable products for home and critical care hemodialysis treatments. The In-Center segment sells blood tubing sets and needles for hemodialysis, primarily to dialysis clinics. This business has a high degree of customer concentration. The Services business provides dialysis to customers at NxStage Kidney Care dialysis centers. NxStage generates the majority of its revenue in the United States.

Ratios

vs
industry
vs
history
PB Ratio 7.11
NXTM's PB Ratio is ranked lower than
84% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.56 vs. NXTM: 7.11 )
Ranked among companies with meaningful PB Ratio only.
NXTM' s PB Ratio Range Over the Past 10 Years
Min: 0.8  Med: 4.7 Max: 14.23
Current: 7.11
0.8
14.23
PS Ratio 3.94
NXTM's PS Ratio is ranked lower than
61% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. NXTM: 3.94 )
Ranked among companies with meaningful PS Ratio only.
NXTM' s PS Ratio Range Over the Past 10 Years
Min: 0.66  Med: 3.61 Max: 16.32
Current: 3.94
0.66
16.32
EV-to-EBITDA 51.30
NXTM's EV-to-EBITDA is ranked lower than
93% of the 203 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.15 vs. NXTM: 51.30 )
Ranked among companies with meaningful EV-to-EBITDA only.
NXTM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1804.3  Med: 47.7 Max: 478.5
Current: 51.3
-1804.3
478.5
Current Ratio 3.17
NXTM's Current Ratio is ranked higher than
63% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. NXTM: 3.17 )
Ranked among companies with meaningful Current Ratio only.
NXTM' s Current Ratio Range Over the Past 10 Years
Min: 1.71  Med: 3.04 Max: 10.48
Current: 3.17
1.71
10.48
Quick Ratio 2.15
NXTM's Quick Ratio is ranked higher than
61% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.67 vs. NXTM: 2.15 )
Ranked among companies with meaningful Quick Ratio only.
NXTM' s Quick Ratio Range Over the Past 10 Years
Min: 0.75  Med: 2.14 Max: 9.59
Current: 2.15
0.75
9.59
Days Inventory 74.76
NXTM's Days Inventory is ranked higher than
82% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.79 vs. NXTM: 74.76 )
Ranked among companies with meaningful Days Inventory only.
NXTM' s Days Inventory Range Over the Past 10 Years
Min: 72.56  Med: 85.16 Max: 111.72
Current: 74.76
72.56
111.72
Days Sales Outstanding 38.32
NXTM's Days Sales Outstanding is ranked higher than
92% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.76 vs. NXTM: 38.32 )
Ranked among companies with meaningful Days Sales Outstanding only.
NXTM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.56  Med: 28.95 Max: 48.64
Current: 38.32
26.56
48.64
Days Payable 31.05
NXTM's Days Payable is ranked lower than
90% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.53 vs. NXTM: 31.05 )
Ranked among companies with meaningful Days Payable only.
NXTM' s Days Payable Range Over the Past 10 Years
Min: 19.2  Med: 40.78 Max: 121.1
Current: 31.05
19.2
121.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.10
NXTM's 3-Year Average Share Buyback Ratio is ranked higher than
56% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.20 vs. NXTM: -2.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NXTM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -143.2  Med: -8.2 Max: -2.1
Current: -2.1
-143.2
-2.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 39.28
NXTM's Price-to-Net-Current-Asset-Value is ranked lower than
93% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.18 vs. NXTM: 39.28 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NXTM' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.77  Med: 47.91 Max: 112.06
Current: 39.28
2.77
112.06
Price-to-Tangible-Book 9.43
NXTM's Price-to-Tangible-Book is ranked lower than
84% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.77 vs. NXTM: 9.43 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NXTM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.38  Med: 7.16 Max: 107.91
Current: 9.43
2.38
107.91
Price-to-Median-PS-Value 1.10
NXTM's Price-to-Median-PS-Value is ranked lower than
60% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. NXTM: 1.10 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NXTM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24  Med: 1.05 Max: 3.86
Current: 1.1
0.24
3.86
Earnings Yield (Greenblatt) % -0.34
NXTM's Earnings Yield (Greenblatt) % is ranked lower than
68% of the 267 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.18 vs. NXTM: -0.34 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NXTM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -89.8  Med: 0 Max: 0
Current: -0.34
-89.8
0
Forward Rate of Return (Yacktman) % 19.99
NXTM's Forward Rate of Return (Yacktman) % is ranked higher than
71% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. NXTM: 19.99 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
NXTM' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -70.3  Med: -3.3 Max: 20.3
Current: 19.99
-70.3
20.3

More Statistics

Revenue (TTM) (Mil) $374.0
EPS (TTM) $ -0.07
Beta0.54
Short Percentage of Float6.10%
52-Week Range $18.28 - 30.80
Shares Outstanding (Mil)65.74

Analyst Estimate

Dec18
Revenue (Mil $)
EPS ($) 0.16
EPS without NRI ($) 0.16
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NXTM

Headlines

Articles On GuruFocus.com
NxStage Announces Second Quarter 2017 Investor Conference Schedule May 25 2017 
NxStage Medical Announces FDA Clearance for its New System One Hemodialysis System May 10 2017 
NxStage® to Report First Quarter 2017 Financial Results Apr 06 2017 
Weekly 3-Year Low Highlights: MFLX, NXTM, CVRR, CMLP Nov 10 2013 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 20,000 Shares Mar 18 2011 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 15,000 Shares Mar 18 2011 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 15,000 Shares Feb 18 2011 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 20,000 Shares Feb 18 2011 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 20,000 Shares Jan 21 2011 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 15,000 Shares Jan 20 2011 

More From Other Websites
NxStage Announces Second Quarter 2017 Investor Conference Schedule May 25 2017
Edited Transcript of NXTM earnings conference call or presentation 9-May-17 1:00pm GMT May 14 2017
NxStage Medical Announces FDA Clearance for its New System One Hemodialysis System May 10 2017
Why NxStage Medical, Inc. Got Hammered Today May 09 2017
NxStage Medical Cuts Its Home Sales Outlook May 09 2017
Investor Network: NxStage Medical, Inc. to Host Earnings Call May 09 2017
NxStage reports 1Q loss May 09 2017
NxStage Reports First Quarter Financial Results May 09 2017
4 Medical Stocks That Could Be Big Winners Next Week May 05 2017
NxStage Medical, Inc. breached its 50 day moving average in a Bearish Manner : NXTM-US : May 4, 2017 May 04 2017
Why Nxstage Medical, Inc. Slumped Today May 03 2017
NxStage Medical, Inc. – Value Analysis (NASDAQ:NXTM) : April 24, 2017 Apr 24 2017
NxStage Medical, Inc. breached its 50 day moving average in a Bullish Manner : NXTM-US : April 21,... Apr 21 2017
NxStage® to Report First Quarter 2017 Financial Results Apr 06 2017
NxStage Medical, Inc. breached its 50 day moving average in a Bearish Manner : NXTM-US : March 21,... Mar 21 2017
NxStage Medical, Inc. breached its 50 day moving average in a Bullish Manner : NXTM-US : March 10,... Mar 10 2017
New Data Shows Significant Potential Cost Savings with On-Site Hemodialysis in Skilled Nursing... Mar 09 2017
NxStage Medical: NxGen Hemodialysis System Now CE Marked Mar 03 2017
NxStage Medical Announces CE Mark for its NxGen Hemodialysis System Mar 02 2017
NxStage Medical, Inc. :NXTM-US: Earnings Analysis: 2016 By the Numbers : March 2, 2017 Mar 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)